{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:35:11Z","timestamp":1782203711389,"version":"3.54.5"},"reference-count":17,"publisher":"American Psychiatric Association Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1999,3,1]]},"DOI":"10.1176\/ajp.156.3.419","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:17:33Z","timestamp":1659111453000},"page":"419-425","source":"Crossref","is-referenced-by-count":73,"title":["Placebo-Controlled Study of the D<sub>4<\/sub>\/5-HT<sub>2A<\/sub> Antagonist Fananserin in the Treatment of Schizophrenia"],"prefix":"10.1176","volume":"156","author":[{"given":"Philippe","family":"Truffinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis F.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Emmanuelle","family":"Rivi\u00ef\u00bf\u00bdre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Papillon-Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1563BABGGJIB","doi-asserted-by":"crossref","unstructured":"Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17:263\u2013287","DOI":"10.1093\/schbul\/17.2.263"},{"key":"R1563BABCAAFC","doi-asserted-by":"crossref","unstructured":"Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O: Cloning of the gene for human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610\u2013614","DOI":"10.1038\/350610a0"},{"key":"R1563BABJAFJB","doi-asserted-by":"crossref","unstructured":"Seeman P, Van Tol HHM: Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15:264\u2013270","DOI":"10.1016\/0165-6147(94)90323-9"},{"key":"R1563BABEBFHC","unstructured":"Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonini values. J Pharmacol Exp Ther 1989; 251:283\u2013246"},{"key":"R1563BABEJADD","doi-asserted-by":"crossref","unstructured":"Heuillet E, Petitet F, Mignani S, Malleron J-L, Lavayre J, N\u00ef\u00bf\u00bdliat G, Doble A, Blanchard J-C: The naphtosultam derivative RP62203 (fananserin) has high affinity for the dopamine D4 receptor. Eur J Pharmacol 1996; 314:229\u2013233","DOI":"10.1016\/S0014-2999(96)00554-7"},{"key":"R1563BABHCBIC","doi-asserted-by":"crossref","unstructured":"Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, Dupuy A, Gu\u00ef\u00bf\u00bdr\u00ef\u00bf\u00bdmy C, M\u00ef\u00bf\u00bdnager J, Zundel J-L, Blanchard J-C: Pharmacological characterization of RP62203, a novel 5-hydroxytryptamine2 receptor antagonist. Br J Pharmacol 1992; 105:27\u201336","DOI":"10.1111\/j.1476-5381.1992.tb14206.x"},{"key":"R1563BABEEAHG","doi-asserted-by":"crossref","unstructured":"Stutzmann J-M, Eon B, Darche F, Lucas M, Rataud J, Piot O, Blanchard J-C, Laduron PM: Are 5-HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 1991; 128:4\u20138","DOI":"10.1016\/0304-3940(91)90747-H"},{"key":"R1563BABGJBDJ","doi-asserted-by":"crossref","unstructured":"Addington D: The use of placebos in clinical trials for acute schizophrenia. Can J Psychiatry 1995; 40:171\u2013176","DOI":"10.1177\/070674379504000403"},{"key":"R1563BABIHJDA","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23:99\u2013110","DOI":"10.1016\/0165-1781(88)90038-8"},{"key":"R1563BABJFABI","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1563BABHEJJG","doi-asserted-by":"crossref","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825\u2013835","DOI":"10.1176\/ajp.151.6.825"},{"key":"R1563BABDJJGE","doi-asserted-by":"crossref","unstructured":"Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782\u2013791","DOI":"10.1176\/ajp.154.6.782"},{"key":"R1563BABIEIDE","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111\u2013123","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"R1563BABJHFEB","doi-asserted-by":"crossref","unstructured":"Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia versus haloperidol. Br J Psychiatry 1995; 166:712\u2013726","DOI":"10.1192\/bjp.166.6.712"},{"key":"R1563BABFADGH","doi-asserted-by":"crossref","unstructured":"Reynolds GP: The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 1996; 51:7\u201311","DOI":"10.2165\/00003495-199651010-00002"},{"key":"R1563BABCEIAE","doi-asserted-by":"crossref","unstructured":"Kramer MS, Last B, Getson A, Reines SA, the D4 Dopamine Antagonist Group: The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997; 54:567\u2013572","DOI":"10.1001\/archpsyc.1997.01830180085011"},{"key":"R1563BABCFHJE","doi-asserted-by":"crossref","unstructured":"Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466\u2013476","DOI":"10.1176\/ajp.153.4.466"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/ajp.156.3.419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T16:13:07Z","timestamp":1721837587000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.156.3.419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3,1]]}},"alternative-id":["10.1176\/ajp.156.3.419"],"URL":"https:\/\/doi.org\/10.1176\/ajp.156.3.419","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3,1]]}}}